Bell Pharmaceuticals And Cosmetics Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 12-12-2024
- Paid Up Capital ₹ 0.50 M
as on 12-12-2024
- Company Age 3 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 12.18 Cr
as on 12-12-2024
- Revenue %
(FY 2023)
- Profit 45315.00%
(FY 2023)
- Ebitda 2090929.33%
(FY 2023)
- Net Worth 27.15%
(FY 2023)
- Total Assets 1846.09%
(FY 2023)
About Bell Pharmaceuticals And Cosmetics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹12.18 Cr.
Yadamakanti Reddy, Someshwar Komuravelli, Anilkumar Gantha, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24290TG2021PTC155399
- Company No.
155399
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Sep 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
K.V.Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bell Pharmaceuticals And Cosmetics?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yadamakanti Reddy  | Director | 29-Sep-2021 | Current |
| Someshwar Komuravelli | Director | 29-Sep-2021 | Current |
| Anilkumar Gantha | Director | 29-Sep-2021 | Current |
| Sampoorna Ganta | Director | 29-Sep-2021 | Current |
| Amudala Yadagiri | Director | 24-May-2023 | Current |
Financial Performance of Bell Pharmaceuticals And Cosmetics.
Bell Pharmaceuticals And Cosmetics Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 45315% increase in profit. The company's net worth Soared by an impressive increase of 27.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bell Pharmaceuticals And Cosmetics?
Unlock access to Bell Pharmaceuticals And Cosmetics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Ciro Pharma Private LimitedActive 3 years 5 monthsYadamakanti Reddy and Someshwar Komuravelli are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Jul 2022 | ₹12.18 Cr | Open |
How Many Employees Work at Bell Pharmaceuticals And Cosmetics?
Unlock and access historical data on people associated with Bell Pharmaceuticals And Cosmetics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bell Pharmaceuticals And Cosmetics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bell Pharmaceuticals And Cosmetics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
